Geron Corp (NASDAQ:GERN)

CAPS Rating: 3 out of 5

A biopharmaceutical company which is developing first-in-class therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS.

Results 1 - 20 of 165 : 1 2 3 4 5 6 7 8 9 Next »

Recs

0
Member Avatar roymarshall (25.54) Submitted: 11/30/2015 2:00:43 PM : Outperform Start Price: $5.10 GERN Score: -42.80

This stock is on fire. Bought at $4.50 and I want to double my money here.

Recs

0
Member Avatar NoDoughBro (69.73) Submitted: 11/30/2015 11:48:04 AM : Outperform Start Price: $5.04 GERN Score: -42.43

Just Creepy. I owned this stock 20 years ago and it was a dud. Let's try it again.

Recs

0
Member Avatar crichards (22.84) Submitted: 11/23/2015 11:29:00 PM : Outperform Start Price: $4.17 GERN Score: -31.07

Great earning, still a large upside @ 4.20

Recs

1
Member Avatar manirg (< 20) Submitted: 8/6/2015 12:19:22 PM : Outperform Start Price: $3.57 GERN Score: -19.49

undervalued, high potential

Recs

0
Member Avatar NiceGuyMax (< 20) Submitted: 3/22/2015 6:52:20 PM : Outperform Start Price: $2.96 GERN Score: -6.30

Someone wil buy them because of Imetelstat becoming a blockbuster drug for small tumor cancer treatment.

Recs

0
Member Avatar TMusta (37.30) Submitted: 3/22/2015 4:23:03 PM : Outperform Start Price: $3.95 GERN Score: -26.08

Imetelstat could be blockbuster drug and a new stadard on cancer treatment.

Recs

0
Member Avatar Nickpar (26.59) Submitted: 1/21/2015 12:53:05 AM : Outperform Start Price: $3.37 GERN Score: -18.04

Lot going on in hot here favor!!!

Recs

0
Member Avatar stockexpert2b (< 20) Submitted: 12/7/2014 10:14:51 PM : Outperform Start Price: $3.75 GERN Score: -23.61

cure for cancer is worth?

Recs

0
Member Avatar oncqueen (68.37) Submitted: 4/3/2014 11:57:03 AM : Outperform Start Price: $2.02 GERN Score: +31.29

This is a very promising drug that is delayed, not dead, and is trading at left-for-dead prices. I'm going to buy some in the real world, too.

Recs

0
Member Avatar fwstash (< 20) Submitted: 1/24/2014 12:50:31 PM : Outperform Start Price: $5.67 GERN Score: -64.25

So what I see is that after having a failed drug and trimming the company's output was smart money. Focusing on a drug that has been treating and working towards a true cure, total remission, get's me excited. As this year progressives Geron will succeed only to the amount the CEO allows, possible a sellout but hopeful for a merge.

Recs

0
Member Avatar LexSC (37.83) Submitted: 12/6/2013 4:34:49 PM : Outperform Start Price: $5.90 GERN Score: -65.47

This a gamble on my part. If the drug they are developing pans out, they can name their price. If not this is a cheap strike out.

Recs

0
Member Avatar cavemantrader (31.77) Submitted: 11/7/2013 11:18:51 AM : Outperform Start Price: $6.75 GERN Score: -74.35

GERN is unique developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Company also has zero debt which is a plus. This will surprise to the upside in a big way.

Recs

2
Member Avatar fatmoneyrz (96.04) Submitted: 10/16/2013 10:29:14 PM : Outperform Start Price: $4.05 GERN Score: -49.65

I've got a mysterious vibe about GERN. When I was walking the city streets very early this morning a fortune teller on a small side street drew me in and wanted to read my palms. While doing so I looked into her crystal ball and saw big $$$, pleasure yachts and Lear jets, and also the letters GERN. The fortune teller stated great wealth was in my future, and stated fundamentals and valuation didn't matter-- that I would buy something that would shoot up to an astronomical degree-- much like a company called ACAD, and I would know it when I saw it. When the market opened this morning I bought GERN.

Recs

2
Member Avatar zzlangerhans (99.78) Submitted: 8/16/2013 12:07:37 AM : Underperform Start Price: $1.52 GERN Score: -64.93

Geron spiked up a little on rather vague descriptions of progress made in the IST of imetelstat for myelofibrosis but I maintain this one surviving indication for one surviving pipeline candidate doesn't merit an enterprise value of more than 100M.

Recs

0
Member Avatar rknapton (63.46) Submitted: 8/6/2013 7:35:50 PM : Underperform Start Price: $1.34 GERN Score: -90.09

Short. Essentially no revenues. Burning through cash rapidly

Recs

0
Member Avatar LouisAIrl (< 20) Submitted: 9/10/2012 11:55:00 AM : Outperform Start Price: $1.25 GERN Score: +83.38

Down too much today

Recs

0
Member Avatar KimLanners (< 20) Submitted: 11/15/2011 7:18:24 PM : Underperform Start Price: $1.68 GERN Score: -3.87

down

Recs

0
Member Avatar Terbius (< 20) Submitted: 9/3/2011 2:39:47 PM : Outperform Start Price: $2.60 GERN Score: -70.99

stem cell research is the most promising new medical technology

Recs

0
Member Avatar StockDoc (< 20) Submitted: 8/27/2011 2:52:54 PM : Outperform Start Price: $2.58 GERN Score: -62.35

Phase 2 study results pending and multi[le applications with core research should push to new highs

Recs

0
Member Avatar GTcollegekid (46.54) Submitted: 7/9/2011 10:21:24 AM : Outperform Start Price: $4.35 GERN Score: -90.01

stem cell

Featured Broker Partners